Concomitant High Apoptosis Inhibitor of Macrophage (AIM) and Low Prostate-Specific Antigen (PSA) Indicates Activated T Cell-Mediated Anticancer Immunity, Enhance Sensitivity to Pembrolizumab, and Elicit Good Prognosis in Prostate Cancer

Concomitant High Apoptosis Inhibitor of Macrophage (AIM) and Low Prostate-Specific Antigen (PSA) Indicates Activated T Cell-Mediated Anticancer Immunity, Enhance Sensitivity to Pembrolizumab, and Elicit Good Prognosis in Prostate Cancer

Background: Despite its widespread use, the use of prostate-specific antigen (PSA) alone as a screening biomarker for prostate cancer (PCa) leads often to unwarranted prostate biopsy, over-diagnosis, and consequently, over-treatment, because of its limited specificity. There are reports that the apo...

Full description

Bibliographic Details
Main Authors: Oluwaseun Adebayo Bamodu, Yuan-Hung Wang, Chi-Tai Yeh, Chen-Hsun Ho, Yi-Te Chiang, Wei-Tang Kao, Chia-Hung Liu, Chia-Chang Wu
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Biomedicines
Subjects:
prostate cancer
apoptosis inhibitor of macrophage
AIM
CD5L
prostate-specific antigen
PSA
Online Access:https://www.mdpi.com/2227-9059/9/9/1225

Similar Items

Similar Items